379 related articles for article (PubMed ID: 34029994)
1. Hepatitis B virus-host interactions and novel targets for viral cure.
Ligat G; Verrier ER; Nassal M; Baumert TF
Curr Opin Virol; 2021 Aug; 49():41-51. PubMed ID: 34029994
[TBL] [Abstract][Full Text] [Related]
2. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
[TBL] [Abstract][Full Text] [Related]
3. Biological basis for functional cure of chronic hepatitis B.
Martinez MG; Testoni B; Zoulim F
J Viral Hepat; 2019 Jul; 26(7):786-794. PubMed ID: 30803126
[TBL] [Abstract][Full Text] [Related]
4. Control and Eradication Strategies of Hepatitis B Virus.
Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
[TBL] [Abstract][Full Text] [Related]
5. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
Durantel D; Zoulim F
J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
[TBL] [Abstract][Full Text] [Related]
6. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
Lin CL; Kao JH
Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus: new therapeutic perspectives.
Lin CL; Yang HC; Kao JH
Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an
Tu T; Budzinska MA; Vondran FWR; Shackel NA; Urban S
J Virol; 2018 Jun; 92(11):. PubMed ID: 29437961
[TBL] [Abstract][Full Text] [Related]
9. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
[TBL] [Abstract][Full Text] [Related]
10. Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation.
Diogo Dias J; Sarica N; Neuveut C
Viruses; 2021 Apr; 13(5):. PubMed ID: 33925977
[TBL] [Abstract][Full Text] [Related]
11. Update on hepatitis B virus infection.
You CR; Lee SW; Jang JW; Yoon SK
World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
[TBL] [Abstract][Full Text] [Related]
12. Ergosterol peroxide inhibits HBV infection by inhibiting the binding of the pre-S1 domain of LHBsAg to NTCP.
Huang H; Huang HC; Chiou WC; Lin LC; Chen JC; Liu HK; Lai YH; Huang C
Antiviral Res; 2021 Nov; 195():105184. PubMed ID: 34627935
[TBL] [Abstract][Full Text] [Related]
13. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
14. Virological Basis for the Cure of Chronic Hepatitis B.
Hu J; Cheng J; Tang L; Hu Z; Luo Y; Li Y; Zhou T; Chang J; Guo JT
ACS Infect Dis; 2019 May; 5(5):659-674. PubMed ID: 29893548
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels.
Ko C; Chakraborty A; Chou WM; Hasreiter J; Wettengel JM; Stadler D; Bester R; Asen T; Zhang K; Wisskirchen K; McKeating JA; Ryu WS; Protzer U
J Hepatol; 2018 Dec; 69(6):1231-1241. PubMed ID: 30142426
[TBL] [Abstract][Full Text] [Related]
16. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the study of hepatitis B virus covalently closed circular DNA.
Ji M; Hu K
Virol Sin; 2017 Dec; 32(6):454-464. PubMed ID: 29280054
[TBL] [Abstract][Full Text] [Related]
18. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
19. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
Nassal M
Gut; 2015 Dec; 64(12):1972-84. PubMed ID: 26048673
[TBL] [Abstract][Full Text] [Related]
20. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
Cheng ST; Hu JL; Ren JH; Yu HB; Zhong S; Wai Wong VK; Kwan Law BY; Chen WX; Xu HM; Zhang ZZ; Cai XF; Hu Y; Zhang WL; Long QX; Ren F; Zhou HZ; Huang AL; Chen J
J Hepatol; 2021 Mar; 74(3):522-534. PubMed ID: 32987030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
